Welcome to our dedicated page for Firefly Neuroscience news (Ticker: AIFF), a resource for investors and traders seeking the latest updates and insights on Firefly Neuroscience stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Firefly Neuroscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Firefly Neuroscience's position in the market.
Firefly Neuroscience (NASDAQ: AIFF) has appointed current board member Greg Lipschitz as Executive Chairman, effective December 3, 2024. Lipschitz, who has served as director since December 2022, brings over 13 years of experience in private equity, merchant banking, capital markets, and finance. He previously served as Vice President of Lazer Capital and currently serves as Managing Director of Old Stone Advisors. The appointment comes as the company prepares to commercialize its AI technology for brain health solutions.
Former Executive Chairman David Johnson has resigned from the board effective November 30, 2024, with no disagreements reported regarding company operations, policies, or practices.
Firefly Neuroscience (NASDAQ: AIFF), an AI company focused on brain health solutions, reported its Q3 2024 results and strategic updates. The company has successfully established partnerships with major pharmaceutical companies including Bright Minds Bioscience, Novartis, and Takeda to advance its FDA-cleared Brain Network Analytics (BNA™) technology. Firefly is pursuing a dual strategy: supporting US neurologists in patient care and collaborating with pharmaceutical companies for drug development. The company leverages a proprietary database of over 77,000 EEG scans across twelve disorders. As of September 30, 2024, Firefly reported cash holdings of $1.2 million and 8,503,365 outstanding shares as of November 12, 2024.
Firefly Neuroscience (NASDAQ: AIFF), an AI company focused on brain health solutions, has announced its participation in the Capital Event Management Conference. The event will take place at the JW Marriott Miami in Aventura, Florida from November 22-24, 2024. The company, which develops innovative solutions for patients with neurological and mental disorders, is offering one-on-one investor meetings during the conference. Interested parties can schedule meetings through CEM representatives or by contacting KCSA Strategic Communications.
Firefly Neuroscience (NASDAQ: AIFF) announced that its Board of Directors has granted 557,885 restricted shares as an inducement grant to David Johnson, the Company's Executive Chairman. The shares will vest in two equal installments at six and twelve months from the grant date, contingent on Johnson's continued service. The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) and falls under the Company's 2024 Long-Term Incentive Plan.
Firefly Neuroscience (NASDAQ: AIFF) has announced a collaboration with Bright Minds Biosciences to analyze data from Bright Minds' positive Phase 1 study using Firefly's AI-powered BNA™ technology. The study focused on Bright Minds' lead compound, BMB-101, and utilized EEG headsets provided by Firefly's partner, Zeto.
The qEEG data analysis demonstrated positive results, with EEG recordings taken at multiple timepoints during the study. Firefly's advanced EEG analysis platform was used to process the data. Jon Olsen, CEO of Firefly, highlighted the value of their AI platform for clinical studies, while Ian McDonald, CEO of Bright Minds, stated that the results validate their approach and indicate that BMB-101 is achieving brain penetration as predicted.
With the completion of this Phase 1 study, BMB-101 is now considered a Phase 2 ready asset, and Bright Minds plans to move forward with an investigative new drug submission.
Firefly Neuroscience (NASDAQ: AIFF) announced that its FDA-510(k) cleared Brain Network Analytics (BNA™) biomarker discovery AI platform will support Arrivo Bioventures' Phase 1 exploratory study of SP-624, a first-in-class SIRT6 activator for major depressive disorder (MDD). The study will evaluate SP-624's impact on neurological pathways and cognitive domains in healthy volunteers and MDD patients.
SP-624 is also being studied in a large Phase 2b trial, focusing on efficacy in females. In a previous Phase 2 study, SP-624 showed statistically significant improvement versus placebo in female subjects with MDD, but not in males. Firefly's BNA™ technology aims to identify target engagement and biomarkers for future neurological studies, potentially addressing the unmet medical need in women's mental health.
Firefly Neuroscience (NASDAQ: AIFF), an AI company focused on improving brain health outcomes, has announced its participation in two upcoming investor conferences in October 2024:
1. Maxim Healthcare Virtual Summit: October 15-17, 2024
- Fireside chat with Maxim Analyst Allen Klee
- Presentation on Thursday, October 17th at 10:00 a.m. ET
2. ThinkEquity Conference: October 30, 2024
- Location: Mandarin Oriental Hotel, New York, NY
- Presentation on Wednesday, October 30th at 11:00 a.m. ET
Webcasts for both events will be available on the company's investor relations website. Investors can schedule one-on-one meetings with management through conference representatives or by contacting KCSA Strategic Communications.
Firefly Neuroscience (NASDAQ: AIFF) has announced advancements in its AI-powered Brain Network Analytics (BNA™) technology following successful research collaborations with Takeda and Novartis. The collaborations demonstrate the value of Firefly's AI-based technology in providing objective measures for neuroscience drug development.
CEO Jon Olsen highlighted that BNA™ technology enables pharmaceutical companies to enhance trial design, accelerate drug candidate advancement, and improve clinical outcomes. The technology offers tools for improved patient and dose selection, potentially reducing costs and development time in CNS drug development.
Firefly aims to expand partnerships with neuroscience pharmaceutical companies, leveraging its unique database and technology. The company believes that electrophysiology-based biomarkers like BNA represent a significant opportunity for neuroscience drug development, especially in addressing concerns about the high cost of new drugs and identifying patients most likely to benefit from them.
Firefly Neuroscience (NASDAQ: AIFF) has announced a strategic partnership with Zeto, a leading EEG brain monitoring technology innovator. The collaboration will integrate Firefly's proprietary Brain Network Analytics (BNA™) technology with Zeto's FDA-cleared EEG platform, currently used in over 200 hospitals and neurology offices nationwide. Firefly will act as a non-exclusive distributor of Zeto's EEG headset devices, cloud platform, and services, expanding its accessibility to healthcare providers.
This partnership aims to offer deeper insights into neurological conditions, potentially improving patient outcomes. Zeto's FDA-cleared EEG headsets (WR19 and Zeto ONE) are designed for various clinical settings, including ICUs, EDs, hospitals, offices, and homes. The integration with Firefly's BNA™ platform is expected to enable more precise analysis and expanded use of EEG technology, optimizing diagnostics for a wide range of neurological disorders.
Firefly Neuroscience (NASDAQ: AIFF), an AI company focused on brain health solutions, has appointed Dr. Stella Vnook to its Board of Directors, effective August 19, 2024. Dr. Vnook, with over 25 years of experience in pharmaceuticals and biotechnology, will serve as Chairperson of the Nominating Committee. She brings expertise as a pharmaceutical executive, entrepreneur, and founder of multiple biotech companies.
Currently, Dr. Vnook is the CEO of Likarda Biotech and Founder and Chair of OralBiolife Biosciences. She also advises several startups and supports innovation at various universities. Her background includes roles at Merck, Jazz Pharmaceuticals, and Catalant. Dr. Vnook holds multiple science degrees, an MBA in Global Marketing, and a Doctorate in Public Health focused on Health Economics.
FAQ
What is the current stock price of Firefly Neuroscience (AIFF)?
What is the market cap of Firefly Neuroscience (AIFF)?
